Form 4: Elevance Health Exec Reports Equity Transactions

Elevance Health's EVP & Chief Health Benefits Officer, Felicia F. Norwood, reported recent acquisitions of restricted stock units and stock options, alongside stock dispositions for tax liabilities.

Summary

• Felicia F. Norwood, EVP & Chief Health Benefits Officer of Elevance Health, Inc. (ELV), reported several transactions involving the company's common stock and derivative securities.
• On March 2, 2026, 1,421 shares of common stock were disposed of at a price of $294.07 per share to cover tax liabilities related to the vesting of previously granted restricted stock.
• On March 2, 2026, 5,951 restricted share units (RSUs) were acquired at a price of $0. These RSUs will vest in installments: 1,983 shares on March 2, 2027, and 1,984 shares each on March 2, 2028, and March 2, 2029.
• Also on March 2, 2026, 2,865 performance-based restricted share units were acquired at a price of $0, with restrictions having lapsed on that date.
• On March 3, 2026, an additional 496 shares of common stock were disposed of at a price of $284.03 per share to cover tax liabilities incident to stock vesting.
• Following these non-derivative transactions, Ms. Norwood beneficially owned 38,838 shares of common stock.
• On March 2, 2026, Ms. Norwood acquired 23,512 employee stock options (right to buy) with an exercise price of $294.07 per share.
• These options become exercisable in three installments, beginning on March 2, 2027, which is the one-year anniversary of the option grant date, and expire on March 2, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation, reflecting standard equity grants and tax-related dispositions, which generally indicates continued alignment of executive interests with shareholder value without introducing new material information.

Positives

• The acquisition of 5,951 restricted share units and 2,865 performance-based restricted share units at a $0 cost indicates executive compensation tied to future company performance and retention.
• The grant of 23,512 employee stock options aligns executive incentives with long-term shareholder value creation, as the options become valuable if the stock price increases above the exercise price.

Negatives

• Dispositions of 1,421 shares at $294.07 and 496 shares at $284.03 were made to cover tax liabilities, which is a standard practice but reduces direct share ownership.

Future Outlook

The filing indicates future vesting events for restricted share units on March 2, 2027, March 2, 2028, and March 2, 2029. Additionally, the granted employee stock options will become exercisable in installments starting March 2, 2027, and will expire on March 2, 2036, aligning executive incentives with long-term company performance.

Industry Context

StockSavvy.ai notes that these transactions are typical for executive compensation packages in the healthcare and insurance industries. The combination of restricted stock units and stock options is a common strategy to attract, retain, and incentivize senior management by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and employee stock options (ESOs) as components of executive compensation is a standard practice across major U.S. public companies, including those in the healthcare sector like UnitedHealth Group (UNH) and Anthem (now Elevance Health itself).
• The vesting schedules for RSUs (multi-year) and the multi-year exercisability of ESOs are consistent with industry benchmarks designed to promote long-term executive retention and performance alignment.
• Dispositions of shares to cover tax liabilities upon vesting are also a routine and expected part of equity compensation plans, observed across virtually all companies that grant equity to executives.

Related Party Transactions

• Acquisition of 5,951 restricted share units by Felicia F. Norwood from Elevance Health, Inc. as part of executive compensation.
• Acquisition of 2,865 performance-based restricted share units by Felicia F. Norwood from Elevance Health, Inc. as part of executive compensation.
• Grant of 23,512 employee stock options to Felicia F. Norwood by Elevance Health, Inc. as part of executive compensation.

Stakeholder Impact

• Shareholders: The equity grants to a key executive reinforce alignment between management's financial interests and the company's long-term performance, potentially benefiting shareholder value.

Next Steps

• Vesting of 1,983 restricted share units on March 2, 2027.
• Employee stock options become exercisable in installments starting March 2, 2027.
• Vesting of 1,984 restricted share units on March 2, 2028.
• Vesting of 1,984 restricted share units on March 2, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the vesting of restricted stock units and the grant of stock options, along with associated tax-related stock dispositions. Such transactions are standard and do not typically signal a change in the company's fundamental outlook or warrant a shift in investment strategy. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

Elevance Health, ELV, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Felicia F. Norwood